Patients with tumors expressing ghrelin have a lower risk for breast cancer death compared to those lacking ghrelin expression in both non-consecutive and selected female patient populations of invasive breast tumors34, as well as in a clinically well-characterized case-control study of lymph node negative patients35. This evidence concerns the gene GHRL and breast cancer.